Sorrento to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies Targeting COVID-19 and Cancer
Shots:
- Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab- initiating with Sorrento’s STI-1499 or COVI-GUARD- currently preclinical studies with an IND submission targeted for Aug’2020.
- The transaction is expected to be close in Aug’2020. The integration of Sorrento's G-MAB Ab library and SmartPharm's GET platform is expected to provide a vast product pipeline of novel- long-acting therapeutic proteins for multiple diseases- including cancer
- STI-1499 is expected to be evaluated in ICU patients to ensure safety and potentially allow a preliminary look at efficacy. In vitro results demonstrated STI-1499's ability to completely neutralize SARS-CoV-2 infection @low doses- making it lead candidate for potential treatment against COVID-19
Ref: Sorrento | Image: SmartPharm
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com